The genotypic inhibitory quotient and the (cumulative) number of mutations predict the response to lopinavir therapy

AIDS

Volumn 20, Issue 7, 2006, Pages 1069-1071

  Hoefnagel, Jolanda G M ^a   Van Der Lee, Manon J ^a   Koopmans, Peter P ^a   Schuurman, Rob ^b   Jurriaans, Suzanne ^c   Van Sighem, Ard I ^d   Gras, Luuk ^d   De Wolf, Frank ^d,e   Galama, Jochem M D ^a   Burger, David M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d STICHTING HIV MONITORING   (Netherlands)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; PROTEINASE INHIBITOR;

ANTIBIOTIC RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG USE; GENE MUTATION; GENOTYPE; GENOTYPIC INHIBITORY QUOTIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; ROC CURVE; VIRUS INHIBITION; VIRUS LOAD;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MUTATION; PYRIMIDINONES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 33646356246     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000222083.44411.02     Document Type: Article

References (10)

1. Hsu A, Isaacson J, Brun S, Bernstein B, Lam W, Bertz R, et al. Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:350-359.
2. Marcelin AG, Lamotte C, Delaugerre C, Ktorza N, Ait MH, Cacace R, et al. Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2003; 47:594-600.
3. Gonzalez R, Gallego O, Valer L, Jimenez-Nacher I, Soriano V. Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. AIDS Res Hum Retroviruses 2004; 20:275-278.
4. Breilh D, Pellegrin I, Rouzes A, Berthoin K, Xuereb F, Budzinski H, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS 2004; 18:1305-1310.
5. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, et al. Drug resistance mutations in HIV-1. Top HIV Med 2003; 11:215-221.
6. Kempf DJ, Isaacson JD, King MS, Brun SC, Xu Y, Real K, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol 2001; 75:7462-7469.
7. Harrigan PR, Wynhoven B, Brumme ZL, Brumme CJ, Sattha B, Major JC, et al. HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach. J Infect Dis 2005; 191:1325-1330.
8. Monno L, Saracino A, Scudeller L, Pastore G, Bonora S, Cargnel A, et al. HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. J Acquir Immune Defic Syndr 2003; 33:439-447.
9. Marcelin AG, Cohen-Codar I, King MS, Colson P, Guillevic E, Descamps D, et al. Virological and pharmacological parameters predicting the response to lopinavir-ritonavir in heavily protease inhibitor-experienced patients. Antimicrob Agents Chemother 2005; 49:1720-1726.
10. de Jong MD, Schuurman R, Lange JM, Boucher CA. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure. Antivir Ther 1996; 1:33-41.